1. What is the Chemxpert database?

Chemxpert database is a techno-commercial information platform developed and operated by Lifescience Intellipedia Pvt. Ltd. Our data provides valuable insights regarding sourcing, marketing, development, and regulatory functions for the entire Lifescience industry. The different industries covered by our data encompass APIs, FDFs, pharma intermediates, paints, dyes, polymers, biotechnology, biochemical, food additives, nutraceuticals, etc.

2. How can I subscribe to the Chemxpert database?

You can gain access to the Chemxpert database after subscribing to it by visiting this link: - https://chemxpert.com/pricing

3. How many countries' data is available on your portal?

The Chemxpert database covers more than 200 countries. We are working in the direction of expanding our data coverage in more countries.

4. What are the different sources you use for obtaining information?

The different sources we use for data collection are as follows: - • Primary researc • DMF, ANDA, & CEP list • Conferences, Exhibitions, & Tradeshow • Company annual reports • DMF, ANDA, & CEP list • Subject matter experts & KOL survey. Apart from these, our other valuable sources include application-wise manufacturers list, subscribed and non-subscribed databases, corporate partners, US FDA Orange book, publicly available sources, industry associates, national statistics, regulatory websites, etc. You can gain access to the Chemxpert database after subscribing to it by visiting this link: -https://chemxpert.com/sources

5. What is the expected time for account activation?

Your Chemxpert account will be activated instantly if the payment is made through our website. If you choose to use RTGS, NEFT, or IMPS systems for payment, your account will be activated within 24 hours.

Date not available
Admin
News Article

HanchorBio Announces Approval for Multi-Regional Clinical Trial of HCB101

HanchorBio has received approval from the Taiwan Food and Drug Administration (TFDA) for its investigational new drug (IND) application, enabling them to proceed with a multi-regional clinical trial of their novel drug candidate, HCB101. This drug is being developed to treat patients with advanced solid tumours or relapsed and refractory non-Hodgkin lymphoma.

HCB101 is created using structure-guided protein design and engineering, along with relevant screening technologies. It consists of an engineered extracellular domain of SIRPα fused to the Fc region of IgG4.

This innovative drug works by triggering the phagocytic activity of macrophages, blocking the "do not eat" signal between macrophages and tumour cells. The extensive in-vitro and in-vivo preclinical data suggest that HCB101 could be a safer and more potent biologic compared to the anti-CD47 monoclonal antibodies and SIRPa fusion proteins currently under investigation in clinical trials.

The clinical trial, known as HCB101-101, will be a multi-regional, multi-centre, open-label, dose-finding, first-in-human (FIH) study involving adults with advanced solid tumours or relapsed and refractory non-Hodgkin lymphoma in both the United States and Taiwan. The primary objectives of this study are to assess the safety, tolerability, pharmacokinetics, and clinical anti-tumour activity of weekly HCB101 intravenous injections.

Let’s apply Data-Driven Pricing to Your APIs

Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.

Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.

Start using market intelligence today and allow yourself to be in control in the API market.

Check it out today and make more informed sourcing decisions! Learn More!